{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:02:13Z","timestamp":1791295333192,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002108","name":"Friedreich's Ataxia Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.neuropharm.2017.05.011","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T12:49:11Z","timestamp":1494506951000},"page":"34-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in\u00a0vitro and in Fxn-deficient KIKO mice in\u00a0vivo"],"prefix":"10.1016","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2126-6417","authenticated-orcid":false,"given":"James L.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Normand L.","family":"Frigon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Pandolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Punnonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2017.05.011_bib1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s12311-008-0036-x","article-title":"Recombinant human erythropoietin increases frataxin protein expression without increasing mRNA expression","volume":"7","author":"Acquaviva","year":"2008","journal-title":"Cerebellum"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/bloodadvances.2016000844","article-title":"Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells","volume":"1","author":"Aihara","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib3","first-page":"953264","article-title":"Erythropoietin in brain development and beyond","volume":"2012","author":"Alnaeeli","year":"2012","journal-title":"Anat. Res. Int."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2217\/rme.09.74","article-title":"Stem cell paracrine actions and tissue regeneration","volume":"5","author":"Baraniak","year":"2010","journal-title":"Regen. Med."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib5","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/blood.V99.10.3813","article-title":"Erythroid differentiation and protoporphyrin IX down-regulate frataxin expression in Friend cells: characterization of frataxin expression compared to molecules involved in iron metabolism and hemoglobinization","volume":"99","author":"Becker","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib6","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/mds.25836","article-title":"Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia","volume":"29","author":"Boesch","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ana.21177","article-title":"Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin","volume":"62","author":"Boesch","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib8","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/mds.22294","article-title":"Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: a clinical pilot trial","volume":"23","author":"Boesch","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib9","doi-asserted-by":"crossref","first-page":"e35685","DOI":"10.1371\/journal.pone.0035685","article-title":"Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis","volume":"7","author":"Boomsma","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib10","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1096\/fj.02-0182com","article-title":"Regulation of the membrane estrogen receptor-alpha: role of cell density, serum, cell passage number, and estradiol","volume":"16","author":"Campbell","year":"2002","journal-title":"Faseb J."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib11","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/hmg\/6.11.1771","article-title":"Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes","volume":"6","author":"Campuzano","year":"1997","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.271.5254.1423","article-title":"Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion","volume":"271","author":"Campuzano","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib13","first-page":"4847","article-title":"Friedreich ataxia induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor","volume":"25","author":"Codazzi","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib14","doi-asserted-by":"crossref","first-page":"18247","DOI":"10.1074\/jbc.M311771200","article-title":"Alternagin-C, a disintegrin-like protein, induces vascular endothelial cell growth factor (VEGF) expression and endothelial cell proliferation in\u00a0vitro","volume":"279","author":"Cominetti","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1136\/jnnp-2013-306788","article-title":"Usefulness of frataxin immunoassays for the diagnosis of Friedreich ataxia","volume":"85","author":"Deutsch","year":"2014","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib16","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM199610173351601","article-title":"Clinical and genetic abnormalities in patients with Friedreich's ataxia","volume":"335","author":"Durr","year":"1996","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib19","first-page":"25","article-title":"Beyond loss of frataxin: the complex molecular pathology of Friedreich ataxia","volume":"17","author":"Evans-Galea","year":"2014","journal-title":"Discov. Med."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0022-1759(82)90034-5","article-title":"Rapid isolation of mononuclear cells from buffy coats prepared by a new blood cell separator","volume":"55","author":"Figdor","year":"1982","journal-title":"J.\u00a0Immunol. Methods"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000022051","article-title":"Effect of in\u00a0vitro aging on the modulation of protein and fibronectin biosynthesis by the elastin-laminin receptor in human skin fibroblasts","volume":"45","author":"Fodil-Bourahla","year":"1999","journal-title":"Gerontology"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib22","doi-asserted-by":"crossref","first-page":"14044","DOI":"10.1038\/mtm.2014.44","article-title":"An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models","volume":"1","author":"Gerard","year":"2014","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib23","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1186\/gb-2007-8-2-r19","article-title":"qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data","volume":"8","author":"Hellemans","year":"2007","journal-title":"Genome Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nchembio815","article-title":"Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia","volume":"2","author":"Herman","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib25","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1006\/exer.1996.0162","article-title":"A\u00a0study of growth factor receptors in human lens epithelial cells and their relationship to fiber differentiation","volume":"63","author":"Ibaraki","year":"1996","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib26","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1093\/hmg\/ddu745","article-title":"Unveiling a common mechanism of apoptosis in beta-cells and neurons in Friedreich's ataxia","volume":"24","author":"Igoillo-Esteve","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-0609.2007.00818.x","article-title":"Erythropoietin after a century of research: younger than ever","volume":"78","author":"Jelkmann","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1083\/jcb.94.2.253","article-title":"Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells","volume":"94","author":"Jones-Villeneuve","year":"1982","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib29","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1128\/MCB.3.12.2271","article-title":"Retinoic acid-induced neural differentiation of embryonal carcinoma cells","volume":"3","author":"Jones-Villeneuve","year":"1983","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib30","first-page":"129","article-title":"Erythropoietin in the neonate","volume":"29","author":"Juul","year":"1999","journal-title":"Curr. Probl. Pediatr."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1203\/00006450-199801000-00007","article-title":"Erythropoietin and erythropoietin receptor in the developing human central nervous system","volume":"43","author":"Juul","year":"1998","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib32","doi-asserted-by":"crossref","first-page":"e26098","DOI":"10.1371\/journal.pone.0026098","article-title":"Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblasts","volume":"6","author":"Kemp","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.14202\/vetworld.2016.605-610","article-title":"Human umbilical mesenchymal stem cells conditioned medium promote primary wound healing regeneration","volume":"9","author":"Kusindarta","year":"2016","journal-title":"Vet. World"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib34","series-title":"Investigation of the Mechanisms of Action of Eltrombopag","author":"Larochelle","year":"2015"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib35","series-title":"Investigation of the Mechanisms of Action of Eltrombopag","author":"Larochelle","year":"2016"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib36","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/acn3.225","article-title":"Frataxin levels in peripheral tissue in Friedreich ataxia","volume":"2","author":"Lazaropoulos","year":"2015","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib37","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/hmg\/ddn127","article-title":"Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia","volume":"17","author":"Li","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib38","doi-asserted-by":"crossref","first-page":"e12286","DOI":"10.1371\/journal.pone.0012286","article-title":"Expression of human frataxin is regulated by transcription factors SRF and TFAP2","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(14)60382-2","article-title":"Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study","volume":"384","author":"Libri","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib40","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ejcb.2015.05.002","article-title":"The role of mitochondria and the CIA machinery in the maturation of cytosolic and nuclear iron-sulfur proteins","volume":"94","author":"Lill","year":"2015","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib41","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1161\/01.ATV.0000098644.03153.6F","article-title":"Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1","volume":"23","author":"Liu","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.abb.2006.09.010","article-title":"Frataxin knockdown causes loss of cytoplasmic iron-sulfur cluster functions, redox alterations and induction of heme transcripts","volume":"457","author":"Lu","year":"2007","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/archneur.59.5.743","article-title":"Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy","volume":"59","author":"Lynch","year":"2002","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib44","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.surneu.2008.02.040","article-title":"Erythropoietin as a neuroprotective agent in traumatic brain injury","volume":"71","author":"Mammis","year":"2009","journal-title":"Surg. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib45","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/mds.24066","article-title":"Erythropoietin in Friedreich ataxia: no effect on frataxin in a randomized controlled trial","volume":"27","author":"Mariotti","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib46","first-page":"135","article-title":"P19 embryonal carcinoma cells","volume":"37","author":"McBurney","year":"1993","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib47","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1083\/jcb.97.2.405","article-title":"Alpha 1- and beta 2-adrenergic receptor expression in the Madin-Darby canine kidney epithelial cell line","volume":"97","author":"Meier","year":"1983","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib48","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1124\/mol.115.098400","article-title":"Discovery and characterization of nonpeptidyl agonists of the tissue-protective erythropoietin receptor","volume":"88","author":"Miller","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0014-5793(02)02251-2","article-title":"Frataxin knockin mouse","volume":"512","author":"Miranda","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.febslet.2004.07.022","article-title":"Frataxin overexpressing mice","volume":"13","author":"Miranda","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib51","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/NEN.0b013e31825fed76","article-title":"Skeletal muscle involvement in friedreich ataxia and potential effects of recombinant human erythropoietin administration on muscle regeneration and neovascularization","volume":"71","author":"Nachbauer","year":"2012","journal-title":"J.\u00a0Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s12311-011-0287-9","article-title":"Effects of erythropoietin on frataxin levels and mitochondrial function in Friedreich ataxia - a dose-response trial","volume":"10","author":"Nachbauer","year":"2011","journal-title":"Cerebellum"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2017.05.011_bib53","first-page":"9","article-title":"The pathogenesis of Friedreich ataxia and the structure and function of frataxin","volume":"256","author":"Pandolfo","year":"2009","journal-title":"J.\u00a0Neurol."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2017.05.011_bib54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/jnc.12317","article-title":"Clinical features of Friedreich's ataxia: classical and atypical phenotypes","volume":"126","author":"Parkinson","year":"2013","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib55","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nm.3510","article-title":"Prevention and reversal of severe mitochondrial cardiomyopathy by gene therapy in a mouse model of Friedreich's ataxia","volume":"20","author":"Perdomini","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pathophys.2012.02.005","article-title":"Erythropoietin neuroprotection with traumatic brain injury","volume":"20","author":"Ponce","year":"2013","journal-title":"Pathophysiology"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2017.05.011_bib57","first-page":"18","article-title":"Multicellular models of Friedreich ataxia","volume":"256","author":"Puccio","year":"2009","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib58","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1152\/physiol.00016.2008","article-title":"Brain protection by erythropoietin: a manifold task","volume":"23","author":"Rabie","year":"2008","journal-title":"Physiology"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib59","doi-asserted-by":"crossref","first-page":"e8825","DOI":"10.1371\/journal.pone.0008825","article-title":"Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model","volume":"5","author":"Rai","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib60","doi-asserted-by":"crossref","first-page":"e1958","DOI":"10.1371\/journal.pone.0001958","article-title":"HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model","volume":"3","author":"Rai","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib61","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1474-4422(14)70321-7","article-title":"Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data","volume":"14","author":"Reetz","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib62","doi-asserted-by":"crossref","first-page":"a012252","DOI":"10.1101\/cshperspect.a012252","article-title":"Regulation of mRNA translation by signaling pathways","volume":"4","author":"Roux","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib63","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mds.23435","article-title":"Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit","volume":"26","author":"Sacc\u00e0","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib64","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/mds.26552","article-title":"Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia","volume":"31","author":"Sacc\u00e0","year":"2016","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib65","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1093\/hmg\/ddu408","article-title":"Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia","volume":"23","author":"Sahdeo","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib66","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.nbd.2011.02.016","article-title":"Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model","volume":"42","author":"Sandi","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib67","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/hmg\/ddn244","article-title":"The in\u00a0vivo mitochondrial two-step maturation of human frataxin","volume":"17","author":"Schmucker","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib68","doi-asserted-by":"crossref","first-page":"R103","DOI":"10.1093\/hmg\/ddq165","article-title":"Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches","volume":"19","author":"Schmucker","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib69","doi-asserted-by":"crossref","first-page":"19343","DOI":"10.1074\/jbc.M000008200","article-title":"Aging fibroblasts present reduced epidermal growth factor (EGF) responsiveness due to preferential loss of EGF receptors","volume":"275","author":"Shiraha","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib70","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cell.2009.01.042","article-title":"Regulation of translation initiation in eukaryotes: mechanisms and biological targets","volume":"136","author":"Sonenberg","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2017.05.011_bib71","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2362.2010.02292.x","article-title":"Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor","volume":"40","author":"Sturm","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib72","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1365-2362.2005.01568.x","article-title":"Recombinant human erythropoietin: effects on frataxin expression in\u00a0vitro","volume":"35","author":"Sturm","year":"2005","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib73","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1757-2215-7-66","article-title":"Expression of the erythropoietin receptor by germline-derived cells - further support for a potential developmental link between the germline and hematopoiesis","volume":"7","author":"Suszynska","year":"2014","journal-title":"J.\u00a0Ovarian Res."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/BJ20101116","article-title":"The Friedreich's ataxia protein frataxin modulates DNA base excision repair in prokaryotes and mammals","volume":"432","author":"Thierbach","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib75","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/hmg\/dds110","article-title":"Interferon gamma upregulates frataxin and corrects the functional deficits in a Friedreich ataxia model","volume":"21","author":"Tomassini","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/156652407780059186","article-title":"Hematopoietic cytokines\u2013on the verge of conquering neurology","volume":"7","author":"Tonges","year":"2007","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib77","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1093\/hmg\/ddr554","article-title":"A\u00a0TAT-frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model","volume":"21","author":"Vyas","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib78","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1042\/BST0340007","article-title":"Coping with stress: eIF2 kinases and translational control","volume":"34","author":"Wek","year":"2006","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib79","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1523\/JNEUROSCI.2381-04.2005","article-title":"Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death","volume":"25","author":"Wogulis","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2017.05.011_bib80","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1186\/bcr958","article-title":"Membrane estrogen receptor-alpha levels in MCF-7 breast cancer cells predict cAMP and proliferation responses","volume":"7","author":"Zivadinovic","year":"2005","journal-title":"Breast Cancer Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390817302174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T19:26:47Z","timestamp":1535830007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390817302174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":80,"alternative-id":["S0028390817302174"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.05.011","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in\u00a0vitro and in Fxn-deficient KIKO mice in\u00a0vivo","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2017.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}